MAPT and Brain atrophy: The pre-phase 1b open-label trial of 12 participants with bvFTD, published in 2022, demonstrated safety and tolerability, and while there was no evidence of change in total tau (t-tau) or phosphorylated tau (p-tau) protein levels, or positive effects on cognition or behavior, the brain atrophy rate decelerated in the majority of participants included in the trial (n = 7) [24].